{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.464.1003.1148","meta":{"versionId":"6","lastUpdated":"2021-11-02T01:01:56.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"NCQA PHEMUR Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2021-11-02"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1148","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.464.1003.1148"}],"version":"20211102","name":"NaltrexoneOral","title":"Naltrexone Oral","status":"active","experimental":false,"date":"2021-11-02T01:01:56-04:00","publisher":"NCQA PHEMUR","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: The purpose of this value set is to represent concepts for naltrexone oral medications.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent generic, human use and prescribable medications.),(Exclusion Criteria: Excludes concepts that represent non-prescribable or branded drugs and excludes concepts that represent components or ingredients.)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","concept":[{"code":"1483744","display":"naltrexone hydrochloride 50 MG Oral Tablet"}]}]},"expansion":{"identifier":"urn:uuid:eec5a534-c7bd-46b0-88ed-61d97f918820","timestamp":"2023-12-11T02:21:17-05:00","total":1,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1483744","display":"naltrexone hydrochloride 50 MG Oral Tablet"}]}}